Six cancer centers have been selected to participate in this process improvement initiative with an overarching aim to help cancer programs and practices improve quality and outcomes of care in patients with stage III and IV NSCLC by improving process pathways for integrated, interdisciplinary communication and care coordination. The participating cancer centers are:
FirstHealth Moore Regional Hospital
Pinehurst, North Carolina
O’Neal Comprehensive Cancer Center at UAB
Saint Francis Cancer Center
Southern Ohio Medical Center
Sutter Health, Sutter Medical Center
This process improvement initiative will encompass five phases:
Phase 1: Site Selection
The Steering Committee peer-ranked applications and selected six cancer programs for participation in a six-month process improvement initiative.
Phase 2: Topic Identification, Quality Measure Development & Education
Selected cancer programs were asked to share quality improvement topics of interest that were relevant to their sites. Full-day workshops are being conducted that include guest faculty serving as subject matter experts, presenting educational lectures, and participating in action planning with the multidisciplinary care team.
Phase 3: Data Collection & Analysis
Once barriers have been identified and a problem statement developed, the participating cancer programs are asked to submit baseline data that will be analyzed and collected at the end of the six-month process improvement.
Phase 4: Implementation of Educational Intervention
Participating cancer programs start their process improvement initiative and provide follow up at one-, three-, and six-month points within the project.
Phase 5: Analyze & Repeat
At the conclusion of the program's project, all data submitted is analyzed and an outcomes report is shared with each cancer program. Programs can opt to use these results to modify their approach and repeat QI within their sites.
If you have questions, please contact Lorna Lucas, MSM, Director, ACCC Provider Education.
This project is made possible by support from AstraZeneca.